Detalles de la búsqueda
1.
Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone.
Blood
; 116(19): 3743-50, 2010 Nov 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-20628153
2.
A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older.
Blood
; 114(6): 1166-73, 2009 Aug 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-19470696
3.
Combined phase I/II study of imexon (AOP99.0001) for treatment of relapsed or refractory multiple myeloma.
Anticancer Drugs
; 21(7): 708-15, 2010 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-20571355
4.
Phase II, randomized, multicenter, comparative study of peginterferon-alpha-2a (40 kD) (Pegasys) versus interferon alpha-2a (Roferon-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemia.
Leuk Lymphoma
; 48(3): 497-505, 2007 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-17454589
5.
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.
Blood
; 109(12): 5143-50, 2007 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-17317857
Resultados
1 -
5
de 5
1
Próxima >
>>